NewGen Provides Business Update
Globe Newswire•16/11/2026•08:00 ET
0
Key Highlights
- ➤US$4.71 million deposited toward Ras Al Khaimah land acquisition
- ➤NX One NMPA registration consultant engaged for China medical-device approval
- ➤IVF business revenue broadly flat in six months ended June 30, 2026
- ➤Cash and equivalents approximately US$1.02 million as of June 30, 2026
- ➤Company completed 2% K25.ai acquisition and agreed to acquire an additional 11%
BANGKOK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today provided an update on its businesses.
In July 2025, the Company acquired advanced cytometry intellectual property and equipment. The Company has engaged Shenzhen Siyu Enterprise Management Consulting Co., Ltd. as its regulatory consultant for registration of its NX One microfluidic platform with China’s National Medical Products Administration (“NMPA”).
Get started
Create a free account to read the full story.
